Prophylactic use of bevacizumab to avoid XXXX following proton therapy for @entity2184 .

@entity1 @entity63 @entity1713 @entity2479 @entity5 @entity1347 @entity2184 @entity11608
PURPOSE: To investigate whether the prophylactic use of bevacizumab reduces the rate of rubeosis after proton therapy for @entity2184 and improves the possibility to treat @entity63 , reapplicated retina with laser photocoagulation. DESIGN: Comparative retrospective case series. METHODS: @entity2184 @entity1 with @entity1713 and treated with proton therapy were included in this institutional study. Twenty-four eyes received prophylactic intravitreal bevacizumab injections and were compared with a control group of 44 eyes without bevacizumab treatment. Bevacizumab injections were performed at the time of @entity11608 clip insertion and were repeated every 2 months during 6 months, and every 3 months thereafter. Ultra-widefield angiography allowed determination of the extent of @entity2479 , which was treated with laser photocoagulation after retinal reapplication. Main outcome measures were the time to rubeosis, the time to retinal reattachment, and the time to laser photocoagulation of @entity63 retina. RESULTS: Baseline characteristics were balanced between the groups, except for thicker @entity5 and larger @entity1713 in the bevacizumab group, potentially to the disadvantage of the study group. Nevertheless, bevacizumab prophylaxis significantly reduced the rate of iris rubeosis from 36% to 4% (log-rank test P = .02) and tended to shorten the time to retinal reapplication until laser photocoagulation of the nonperfusion areas could be performed. CONCLUSIONS: Prophylactic intravitreal bevacizumab in @entity1 treated with proton therapy for @entity2184 with @entity1713 prevented @entity1347 , until laser photocoagulation to the reapplied retina could be performed.
